Question Bank › Sequential re-rating

Sequential re-rating

Sequential re-rating: management describes the same offering landing bigger the second and third time around

Calls Tested
498
Answered YES
7
Hit Rate
1.4%
rare by design

Pediatrix Medical Group, Inc. (MD) — this company's answers

NO on the Q3 2021 call 2021-10-28 B
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. The transcript discusses growth in volumes, acquisitions, and expansion of clinics. Specifically, they mention opening more than 100 pediatric clinics across their footprint within a few years. But is that about the size of individual engagements? They talk about growth efforts, acquisitions, and de novo development. They mention that acquisitions haven't been a major part of activity so far this year, but could play a role. They also mention the Brave Care investment and plans to open clinics. However, the question is about whether the individual size of what they land is growing versus their own past. They talk about expanding practices, adding practices, and enhancing hospital relationships. But do they explicitly say that each new engagement is bigger? They mention that they are building momentum, and that volumes exceed pre-COVID levels. But that's about overall volume, not unit size. They also mention that they expect adjusted EBITDA to exceed $270 million next year, but that's financial guidance. The key is whether management conveys that the deals, contracts, projects, etc., are individually larger. They talk about opening more than 100 pediatric clinics, but that's a plan, not something already signed. They also mention that they are in discussions with existing platforms for acquisitions. But they don't say that these are larger than past acquisitions. They don't compare the size of new contracts to old ones. They talk about growth in NICU days, volumes, etc., but that's volume growth, not necessarily larger unit size per engagement. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see any such statement. They talk about expanding practices, but that might be adding more practices, not making each practice larger. They talk about the Brave Care investment and opening clinics, but that's a new venture, not necessarily the same offering as before.

← Back to the full MD analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE — that is, does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon as a present-tense reality: the unit size of the company's own repeatable business is escalating. Any genuine expression of this counts, and the form varies widely across industries. For example — management noting that the average size of new orders, contracts, or deals has stepped up versus what the company used to sign; that its newest customers are starting at a level its early customers took years to reach, or are entering at broader scope from the outset; that where it once sold a single unit, department, site, or product, the same type of buyer now commits to many at once; that follow-on commitments from the same counterparties are arriving at multiples of the initial ones; that the projects, programs, or engagements it is now being awarded are individually larger or longer-dated than its historical norm; that initial commitments increasingly arrive as full deployments rather than as trials; or that the largest single piece of business in the company's history was just signed and management presents it as part of an upward drift in deal size rather than an isolated event. Three things should come through in management's own voice. First, A COMPARISON AGAINST THE COMPANY'S OWN RECENT PAST — management contrasts the size or scope of what it is landing now with what it was landing before for substantially the same offering, so the point is escalation of unit size, not merely more units or a good quarter. Second, ALREADY REAL AND RECURRING — the larger instances are things actually signed, ordered, awarded, or begun in the recent period, and management conveys a pattern rather than one exceptional event; a single record deal counts only if management frames it as part of an upward drift in the size of what the company is winning. Third, EARLY — management conveys, directly or plainly in substance, that this escalation is recent enough that the reported results still largely reflect the smaller-instance era, and that further instances at the new, larger size are already forming, in negotiation, or expected to keep arriving. Answer NO if management simply reports strong demand, more customers, higher revenue, or a good quarter without conveying that the individual size of what it lands has grown versus its own past. NO if the growth described comes purely from volume — more of the same-sized business — or from price increases on unchanged scope. NO if larger deals are only hoped for, targeted, sitting in a pipeline, or described as an ambition to move upmarket. NO if the only evidence is one outsized transaction that management itself treats as exceptional or non-repeating. NO if large engagements have always been the ordinary unit of this company's business and nothing about their size has changed. NO if management is chiefly describing deal sizes shrinking, scopes being cut, customers downsizing commitments, or contracts being renegotiated smaller. NO if the escalation is already mature and fully reflected in current results, with nothing further ahead. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+

How the model reasoned

AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.

More from the question bank

Answers go deeper than the scriptFresh evidence outrunning the reported numbeSold before it existsCustomers coming back on their ownPromise already turning into factThe open question just closedAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.